New consensus on assessing carcinogenic risks of gene therapies

A new article in the peer-reviewed journal Human Gene Therapy describes the consensus reached by invited experts who participated in a meeting to evaluate the potential carcinogenicity of gene therapies.

Professor Inga Neumann advances understanding of oxytocin and social fear

In a comprehensive Genomic Press Interview, Professor Inga Neumann, Chair of the Department of Behavioural and Molecular Neurobiology at the University of Regensburg, reveals groundbreaking

December 24, 2024

Kymera’s novel MDM2 degrader granted orphan designation for AML – Pharmaceutical Technology

Kymera’s KT-253 is being explored in a variety of liquid and solid tumours. Source: Shutterstock / Juan Gaertner. Clinical-stage biopharma Kymera Therapeutics has announced that

June 23, 2023

Higher level of maternal autistic traits associated with increased risk of preterm birth

Researchers investigated the association between maternal autistic traits and the risk of adverse birth outcomes in the general population.

January 24, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.